Recruiting EARLY_PHASE1 INTERVENTIONAL 2-arm NCT04603872

CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies

Clinical Trial for the Safety and Efficacy of CD19/BCMA-targeted CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Acute Lymphoblastic Leukemia, B-cell Non-Hodgkin's Lymphoma and Multiple Myeloma

Sponsor: Yake Biotechnology Ltd.

Conditions Acute Lymphoblastic Leukemia, in Relapse Acute Lymphocytic Leukaemia Refractory Multiple Myeloma in Relapse Multiple Myeloma, Refractory Non-Hodgkin's Lymphoma Refractory Non-Hodgkin's Lymphoma, Relapsed

Interventions CD19/BCMA Targeted CAR T-cells CD19/BCMA Targeted CAR T-cells and dasatinib

Updated 4 times since 2020 Last updated: Oct 27, 2020 Started: Nov 1, 2020 Primary completion: Nov 1, 2023 Completion: Nov 1, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This EARLY_PHASE1 trial investigates Acute Lymphoblastic Leukemia, in Relapse and Acute Lymphocytic Leukaemia Refractory and is currently actively recruiting participants. Yake Biotechnology Ltd. leads this study, which shows 4 recorded versions since 2020 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Recruiting EARLY_PHASE1
Jul 2024 — Sep 2024 [monthly]

Recruiting EARLY_PHASE1
Jan 2021 — Jul 2024 [monthly]

Recruiting EARLY_PHASE1
Nov 2020 — Jan 2021 [monthly]

Recruiting EARLY_PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Yake Biotechnology Ltd.
Zhejiang University

Data source: Zhejiang University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hangzhou, China